Uridine
(Synonyms: 尿苷; β-Uridine) 目录号 : GC13742
Uridine是一种核苷，包含尿嘧啶，通过β-N1-糖苷键与核糖环连接。
Cas No.:58-96-8
Sample solution is provided at 25 µL, 10mM.
Uridine is a nucleoside that contains uracil and is linked to the ribose ring through a β-N1-glycosidic bond [1]. Uridine regulates enzymes and intermediates in the Uridine metabolism (such as UTP, DHODH, and UPase) and is associated with glucose homeostasis, lipid metabolism, and amino acid metabolism [2-3].
In vitro, Uridine (6-24mM; 7 days) dose-dependently inhibits the proliferation of leukemia cells HL-60 and induces HL-60 to differentiate into mature cells with monocyte and granulocyte characteristics [1]. Uridine (0.2-0.4mg/mL; 10h) reduces hepatocyte apoptosis caused by CCl4, significantly reduces the expression of Caspase-3 and Bax, and upregulates Bcl-2 expression [4].
In vivo, Uridine (10-20mg/kg; oral; 6 weeks) alleviates liver fibrosis in mice with CCl4-induced liver fibrosis model and inhibits the expression of pro-inflammatory cytokines and the activation of the NF-κB signaling pathway [4]. Uridine (30mg/kg; iv; single dose) significantly increases the UDP and UTP contents in the myocardium of rats with acute myocardial ischemia (AMI) and ischemia/reperfusion injury (I/R), reduces CrP and ATP levels, and significantly reduces the size of the ischemic area in the myocardium [5].
References:
[1] Sokoloski JA, et al., Effects of uridine on the growth and differentiation of HL-60 leukemia cells. Leuk Res. 1991;15(11):1051-8.
[2] Zhang Y, Guo S, Xie C, et al. Uridine metabolism and its role in glucose, lipid, and amino acid homeostasis[J]. BioMed research international, 2020, 2020(1): 7091718.
[3] Chenna Narendra S, Chalise J P, Magnusson M, et al. Local but not systemic administration of uridine prevents development of antigen-induced arthritis[J]. PloS one, 2015, 10(10): e0141863.
[4] Zheng W V, Li Y, Cheng X, et al. Uridine alleviates carbon tetrachloride‐induced liver fibrosis by regulating the activity of liver‐related cells[J]. Journal of Cellular and Molecular Medicine, 2022, 26(3): 840-854.
[5] Krylova IB, Selina EN, Bulion VV, et al. Uridine treatment prevents myocardial injury in rat models of acute ischemia and ischemia/reperfusion by activating the mitochondrial ATP-dependent potassium channel. Sci Rep. 2021;11(1):16999.
Uridine是一种核苷，包含尿嘧啶，通过β-N1-糖苷键与核糖环连接 [1]。Uridine通过调节尿苷代谢中的酶和中间体（如 UTP、DHODH和UPase）与葡萄糖稳态、脂质代谢和氨基酸代谢相关 [2-3]。
在体外，Uridine（6-24mM; 7 days）剂量依赖性地抑制白血病细胞HL-60的增殖，并诱导HL-60分化为具有单核细胞和粒细胞特征的成熟细胞 [1]。Uridine（0.2-0.4mg/mL; 10h）减少了CCl4引起的肝细胞凋亡，显著降低Caspase-3和Bax的表达，并上调Bcl-2表达 [4]。
在体内，Uridine（10-20mg/kg; oral; 6 weeks）缓解了CCl4诱导肝纤维化模型小鼠的肝纤维化，并且抑制了促炎细胞因子的表达和NF-κB信号通路的激活 [4]。Uridine（30mg/kg; iv single dose）显著增加了急性心肌缺血（AMI ）和缺血/再灌注损伤（I/R）大鼠心肌UDP和UTP含量，降低CrP和ATP水平，显著减小了心肌中缺血区域的大小 [5]。
| Cell experiment [1]: | |
Cell lines | AML12 cells |
Preparation Method | To avoid the adverse effects of hepatocyte injury produced during perfusion, the mouse hepatocyte cell line (AML12, the mouse hepatocyte cell line) was also used to check the protective effects of Uridine on hepatocytes apoptosis caused by CCl4. Before 4h prior to treatment with 10mmol/L CCl4 for 10h, the hepatocytes were treated with Uridine (200µg/ml) or the vehicle (DMSO). Cell apoptosis rate was assessed using a PE Annexin V apoptosis detection kit according to the manufacturer's instructions. The cell samples were analysed with a FACSCalibur flow cytometer (Becton-Dickinson), and cells that are viable are Annexin V-PE and 7-AAD negative; cells that are in early apoptosis are Annexin V-PE positive and 7-AAD negative; and cells that are in late apoptosis or already dead are both Annexin V-PE and 7-AAD positive. |
Reaction Conditions | 200µg/ml; 10h |
Applications | Uridine reduced hepatocyte apoptosis induced by CCl4, significantly decreased the expression of Caspase-3 and Bax, and upregulated the expression of Bcl-2. |
| Animal experiment [1]: | |
Animal models | C57BL/6J mice |
Preparation Method | The establishment of the experimental mouse model was approved by the Animal Ethics Committee of the Intervention and Cell Therapy Center of Peking University Shenzhen Hospital. 30 healthy C57BL/6J mice were chosen (6–7 weeks old, weighing between 19 ± 2g) and randomly divided them into control group, model group and Uridine treatment group. Model group: CCl4 was mixed with olive oil into a 10% oily solvent, the mice from the model group were injected intraperitoneally with the mixed solution at 0.6μl/g twice per week for 8 weeks; Control group: the C57BL/6J mice were injected intraperitoneally with the same volume of olive oil at the same time point (as negative control); Uridine treatment group, the mice were given Uridine by drinking water (10–20mg/kg) for 6 weeks. Twenty‐four hours after the last injection, the eyeballs of experimental animals were removed and blood was collected. The mice were anaesthetized and perfused with saline. The liver tissues were collected for a series of biological analyses. |
Dosage form | 10-20mg/kg/day for 6 weeks; oral |
Applications | Uridine alleviated liver fibrosis in mice with CCl4-induced liver fibrosis model, and inhibited the expression of pro-inflammatory cytokines and the activation of the NF-κB signaling pathway. |
References: | |
| Cas No. | 58-96-8 | SDF | |
| 别名 | 尿苷; β-Uridine | ||
| 化学名 | 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione | ||
| Canonical SMILES | C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O | ||
| 分子式 | C9H12N2O6 | 分子量 | 244.2 |
| 溶解度 | ≥ 71.4mg/mL in DMSO | 储存条件 | Store at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.095 mL | 20.475 mL | 40.95 mL |
| 5 mM | 0.819 mL | 4.095 mL | 8.19 mL |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.095 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet